Ocular toxicity due to Trametinib and Dabrafenib
| Autor: | Michael Neumayer, Stephanie Sarny, Julian Kofler, Yosuf El-Shabrawi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Metastatic Cutaneous Melanoma genetic structures Pyridones Case Report Antineoplastic Agents Pyrimidinones Uveitis 03 medical and health sciences 0302 clinical medicine Ocular toxicity lcsh:Ophthalmology Trametinib Ophthalmology Oximes medicine Humans Uveitis anterior Protein Kinase Inhibitors Aged business.industry Dabrafenib Imidazoles Retinal Detachment General Medicine medicine.disease eye diseases Neuroretinal detachment Serous fluid lcsh:RE1-994 030220 oncology & carcinogenesis 030221 ophthalmology & optometry White Spots sense organs Stage iv business medicine.drug |
| Zdroj: | BMC Ophthalmology, Vol 17, Iss 1, Pp 1-3 (2017) BMC Ophthalmology |
| ISSN: | 1471-2415 |
| DOI: | 10.1186/s12886-017-0541-0 |
| Popis: | Background To report a case of uveitis and neuroretinal detachment in a patient treated with Trametinib and Dabrafenib due to metastatic cutaneous melanoma stage IV. Case presentation We evaluated slit lamp examination, fundoscopy, optical coherence tomography, fluorescein and indocyanine green angiography in a 66 years old man suffering visual loss. Fundoscopy showed serous neuroretinal detachment of the fovea accompanied with white spots surrounding the fovea in both eyes. Although therapy with Trametinib and Dabrafenib was stopped uveitis anterior was seen 2 weeks later. After a year, the therapy was started again and the serous neuroretinal detachment appeared once more, however without inflammatory reaction of the anterior chamber. Conclusion Patients treated with Trametinib and Dabrafenib should undergo consecutive eye examinations from the beginning of the therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink